Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02495233 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | terminated | Phase 1 / Phase 2 | 10 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02500927 | A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations | terminated | Phase 2 | 31 | Astellas Pharma Inc |
| 1 |
| Nov 20, 2024 |
| clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 / Phase 2 | 124 | Astellas Pharma IncINDUSTRY | 3 | Nov 14, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT01088906 | Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC(Phalcis) | terminated | Phase 2 | 57 | Spanish Lung Cancer GroupOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05492045 | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 22 | InventisBio Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT04139317 | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | terminated | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 9, 2024 | clinicaltrials |
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | terminated | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | Oct 9, 2024 | clinicaltrials |
| NCT05397171 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | terminated | Phase 1 / Phase 2 | 17 | AstraZenecaINDUSTRY | 2 | Oct 1, 2024 | clinicaltrials |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 29, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT03050554 | SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 2 | Andrew SharabiOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT00998166 | A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT06507891 | A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | terminated | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT02954523 | Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | terminated | Phase 1 / Phase 2 | 10 | Chul KimOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT02949843 | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | terminated | Phase 2 | 19 | Wake Forest University Health SciencesOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04908956 | Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)(STEREO) | terminated | Phase 2 | 6 | ETOP IBCSG Partners FoundationNETWORK | 8 | Jun 28, 2024 | clinicaltrials |
| NCT04402008 | Study of Poziotinib in Japanese Patients With NSCLC | terminated | Phase 1 / Phase 2 | 42 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.(CANOPY-N) | terminated | Phase 2 | 88 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 20, 2024 | clinicaltrials |
| NCT04037462 | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy | terminated | Phase 1 / Phase 2 | 2 | VA Office of Research and DevelopmentFED | 1 | Jun 14, 2024 | clinicaltrials |
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT04476797 | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC(GRECO-1) | terminated | Phase 1 / Phase 2 | 47 | Galera Therapeutics, Inc.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04211922 | Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | terminated | Phase 2 | 4 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT02954991 | Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer | terminated | Phase 2 | 161 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04772053 | Molecular Disease Characterization Initiative (MDCI) | terminated | Phase 2 | 6 | GlaxoSmithKlineINDUSTRY | 2 | Apr 19, 2024 | clinicaltrials |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03472560 | A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF) | terminated | Phase 2 | 61 | PfizerINDUSTRY | 8 | Apr 9, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study(PIL) | terminated | Phase 1 / Phase 2 | 4 | Asha NayakOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy(FLT3) | terminated | Phase 1 / Phase 2 | 5 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05176925 | Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC | terminated | Phase 2 | 5 | Fudan UniversityOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 153 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04099836 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | terminated | Phase 2 | 7 | Duke UniversityOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT01514864 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | terminated | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 7 | Dec 19, 2023 | clinicaltrials |
| NCT03386929 | Survival Prolongation by Rationale Innovative Genomics(SPRING) | terminated | Phase 1 / Phase 2 | 15 | Worldwide Innovative Network AssociationOTHER | 4 | Dec 18, 2023 | clinicaltrials |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | terminated | Phase 2 | 1 | Achilles Therapeutics UK LimitedINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03871153 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | Greg Durm, MDOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03228186 | Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04739358 | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | terminated | Phase 1 / Phase 2 | 2 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03425006 | Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | terminated | Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 27, 2024source: clinicaltrials